SERPINA1 (Alpha-1-Antitrypsin) Drug Discovery Landscape & Assay Solutions
- By admin
- 07 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Alpha-1 Antitrypsin Deficiency (AATD) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SERPINA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPINA1 Wild-Type (PiM) & Mutant (PiZ) Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed (Native Glycosylation). |
View SERPINA1 Products |
| Gene Delivery | SERPINA1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for cell-based corrector screening. |
View SERPINA1 Products |
| Benchmark Ab | Anti-SERPINA1 Benchmark Antibody Recombinant positive control for assay standardization. |
View SERPINA1 Products |
| Validator | SERPINA1 siRNA Set For knockdown verification in hepatocyte models. |
View SERPINA1 Products |
| Related Target A | ELANE (Neutrophil Elastase) Primary biological target of SERPINA1; essential for functional inhibition assays. |
View ELANE Products |
| Related Target B | HNF4A Upstream transcriptional regulator of SERPINA1 expression. |
View HNF4A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pathological Conformation Modeling | PiZ mutant proteins available with exact sequence verification and native HEK293 folding to mimic in vivo polymerization. |
| Functional Inhibition Screening | Highly purified, Endotoxin-controlled (<1EU/ug) WT SERPINA1 for reliable neutrophil elastase inhibition baselines. |
| Lack of Reliable Controls | Sequence-verified Recombinant benchmark antibodies included for precise western blot and ELISA standardization. |
| False Positives in Knockdown Studies | Validated siRNA sets included for rigorous specificity checks in RNAi/CRISPR development. |
Live SERPINA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SERPINA1 (Alpha-1-Antitrypsin) therapeutics is intensifying, with major players shifting focus from traditional plasma-derived augmentation therapies to RNA interference (RNAi), gene editing, and small molecule correctors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual pathological mechanisms of Alpha-1 Antitrypsin Deficiency (AATD): the loss-of-function in the lungs (emphysema) and the toxic gain-of-function in the liver (hepatocyte damage due to misfolded PiZ mutant accumulation). Future pipelines are heavily oriented towards combination approaches—silencing endogenous mutant protein while delivering wild-type genes, or developing chaperones that facilitate proper mutant secretion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi / siRNA | Arrowhead, Takeda, Dicerna | AATD Liver Disease | Knockdown Validation (Need High-Purity siRNA & Detection Abs) |
| Small Molecule Correctors | Vertex Pharmaceuticals | AATD Lung & Liver Disease | Conformational Assays (Need HEK293-expressed PiZ Mutant Proteins) |
| Gene Therapy / CRISPR | Intellia, Apic Bio, Beam | AATD Genetic Correction | Stable Expression Models (Need Lentiviral WT/Mutant Constructs) |
| Recombinant Protein (rAAT) | Kamada, Inhibrx | AATD Emphysema | PK/PD & Activity Testing (Need Reliable Benchmark Antibodies) |